Sellas Life Sciences Stock Performance
| SLS Stock | USD 1.17 0.05 4.10% |
The entity has a beta of 0.13, which indicates not very significant fluctuations relative to the market. As returns on the market increase, Sellas Life's returns are expected to increase less than the market. However, during the bear market, the loss of holding Sellas Life is expected to be smaller as well. At this point, Sellas Life Sciences has a negative expected return of -0.12%. Please make sure to validate Sellas Life's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and market facilitation index , to decide if Sellas Life Sciences performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Sellas Life Sciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of latest weak performance, the Stock's essential indicators remain stable and the newest uproar on Wall Street may also be a sign of mid-term gains for the firm private investors. ...more
Last Split Factor 1:50 | Dividend Date 2019-11-08 | Last Split Date 2019-11-08 |
1 | Sodium Lauryl Sulfate Market is Projected to Grow at a 5.1 percent CAGR, Expected to Hit USD US 1.66 Billion by 2034 Fact.MR | 09/05/2024 |
2 | Sellas Life Sciences Group Inc A Bull Case Theory | 09/18/2024 |
3 | Solaris Reports 87m of 1.23 percent CuEq, 93m of 1.01 percent CuEq and 84m of 1.00 percent CuEq Improving Modelled Grades Near Surface in MRE | 10/07/2024 |
4 | SELLAS Life Sciences to Participate in Fireside Chat at the 2024 Maxim Healthcare Virtual Summit | 10/10/2024 |
5 | Monster Energys Giovanni Vianna Takes Second Place in Mens Skateboard Street Liz Akama Claims Second in Womens Skateboard Street at SLS Sydney 2024 | 10/14/2024 |
6 | SELLAS Announces U.S. FDA Rare Pediatric Disease Designation Granted to Galinpepimut-S for the Treatment of Pediatric Acute Myeloid Leukemia | 10/15/2024 |
7 | SELLAS Life Sciences to Present at the 66th American Society of Hematology Annual Meeting Exposition 2024 | 11/05/2024 |
8 | Sellas Life Sciences options imply 22.6 percent move in share price post-earnings - TipRanks | 11/11/2024 |
| Begin Period Cash Flow | 17.2 M | |
| Free Cash Flow | -36.9 M |
Sellas |
Sellas Life Relative Risk vs. Return Landscape
If you would invest 130.00 in Sellas Life Sciences on August 28, 2024 and sell it today you would lose (13.00) from holding Sellas Life Sciences or give up 10.0% of portfolio value over 90 days. Sellas Life Sciences is generating negative expected returns assuming volatility of 3.1139% on return distribution over 90 days investment horizon. In other words, 27% of stocks are less volatile than Sellas, and above 99% of all equities are expected to generate higher returns over the next 90 days. Expected Return |
| Risk |
Sellas Life Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Sellas Life's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Sellas Life Sciences, and traders can use it to determine the average amount a Sellas Life's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0387
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | SLS |
Estimated Market Risk
| 3.11 actual daily | 27 73% of assets are more volatile |
Expected Return
| -0.12 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.04 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Sellas Life is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Sellas Life by adding Sellas Life to a well-diversified portfolio.
Sellas Life Fundamentals Growth
Sellas Stock prices reflect investors' perceptions of the future prospects and financial health of Sellas Life, and Sellas Life fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Sellas Stock performance.
| Return On Equity | -8.88 | ||||
| Return On Asset | -1.29 | ||||
| Current Valuation | 61.89 M | ||||
| Shares Outstanding | 70.38 M | ||||
| Price To Book | 5.18 X | ||||
| Price To Sales | 26.90 X | ||||
| Gross Profit | 900 K | ||||
| EBITDA | 529 K | ||||
| Net Income | (37.34 M) | ||||
| Cash And Equivalents | 26.99 M | ||||
| Cash Per Share | 1.31 X | ||||
| Total Debt | 906 K | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 2.36 X | ||||
| Book Value Per Share | (0.25) X | ||||
| Cash Flow From Operations | (31.41 M) | ||||
| Earnings Per Share | (0.67) X | ||||
| Market Capitalization | 82.35 M | ||||
| Total Asset | 6.22 M | ||||
| Retained Earnings | (217.24 M) | ||||
| Working Capital | (10.56 M) | ||||
About Sellas Life Performance
Assessing Sellas Life's fundamental ratios provides investors with valuable insights into Sellas Life's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Sellas Life is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | -23.1 K | -21.9 K | |
| Return On Tangible Assets | (8.67) | (9.11) | |
| Return On Capital Employed | 5.04 | 5.29 | |
| Return On Assets | (6.00) | (6.30) | |
| Return On Equity | 4.68 | 4.92 |
Things to note about Sellas Life Sciences performance evaluation
Checking the ongoing alerts about Sellas Life for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Sellas Life Sciences help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Sellas Life Sciences generated a negative expected return over the last 90 days | |
| Sellas Life Sciences may become a speculative penny stock | |
| Sellas Life Sciences has high historical volatility and very poor performance | |
| Reported Net Loss for the year was (37.34 M) with profit before taxes, overhead, and interest of 900 K. | |
| Sellas Life Sciences has about 26.99 M in cash with (31.41 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.31, which can makes it an attractive takeover target, given it will continue generating positive cash flow. | |
| Sellas Life Sciences has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: Sellas Life Sciences options imply 22.6 percent move in share price post-earnings - TipRanks |
- Analyzing Sellas Life's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Sellas Life's stock is overvalued or undervalued compared to its peers.
- Examining Sellas Life's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Sellas Life's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Sellas Life's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Sellas Life's stock. These opinions can provide insight into Sellas Life's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Sellas Stock Analysis
When running Sellas Life's price analysis, check to measure Sellas Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Sellas Life is operating at the current time. Most of Sellas Life's value examination focuses on studying past and present price action to predict the probability of Sellas Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Sellas Life's price. Additionally, you may evaluate how the addition of Sellas Life to your portfolios can decrease your overall portfolio volatility.